- Home
- EDU vs LEGN Comparison
EDU vs LEGN Comparison
Compare EDU & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- LEGN
- Stock Information
- Founded
- EDU 1993
- LEGN 2014
- Country
- EDU China
- LEGN United States
- Employees
- EDU N/A
- LEGN N/A
- Industry
- EDU Other Consumer Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EDU Real Estate
- LEGN Health Care
- Exchange
- EDU Nasdaq
- LEGN Nasdaq
- Market Cap
- EDU 7.3B
- LEGN 5.4B
- IPO Year
- EDU 2006
- LEGN 2020
- Fundamental
- Price
- EDU $52.32
- LEGN $38.96
- Analyst Decision
- EDU Buy
- LEGN Strong Buy
- Analyst Count
- EDU 4
- LEGN 12
- Target Price
- EDU $52.00
- LEGN $73.91
- AVG Volume (30 Days)
- EDU 979.8K
- LEGN 1.6M
- Earning Date
- EDU 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- EDU 1.11%
- LEGN N/A
- EPS Growth
- EDU 27.46
- LEGN N/A
- EPS
- EDU 2.29
- LEGN N/A
- Revenue
- EDU $4,793,786,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EDU $13.57
- LEGN $65.49
- Revenue Next Year
- EDU $13.00
- LEGN $53.76
- P/E Ratio
- EDU $23.09
- LEGN N/A
- Revenue Growth
- EDU 18.73
- LEGN 112.46
- 52 Week Low
- EDU $40.66
- LEGN $27.34
- 52 Week High
- EDU $87.26
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EDU 56.52
- LEGN 66.26
- Support Level
- EDU $50.45
- LEGN $34.64
- Resistance Level
- EDU $54.30
- LEGN $39.88
- Average True Range (ATR)
- EDU 1.76
- LEGN 1.46
- MACD
- EDU -0.07
- LEGN 0.37
- Stochastic Oscillator
- EDU 61.85
- LEGN 87.67
About EDU New Oriental Education & Technology Group Inc.
New Oriental is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation, consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.